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Background: Interactions between Th1 and Th2 immune responses are of importance to the onset and
development of allergic disorders. A Toll-like receptor 7 agonist such as AZD8848 may have potential as a
treatment for allergic airway disease by skewing the immune system away from a Th2 profile.
Objective: To evaluate the efficacy and safety of intranasal AZD8848.
Methods: In a placebo-controlled single ascending dose study, AZD8848 (0.3-600 μg) was given intranasally to 48
healthy subjects and 12 patients with allergic rhinitis (NCT00688779). In a placebo-controlled repeat challenge/
treatment study, AZD8848 (30 and 60 μg) was given once weekly for five weeks to 74 patients with allergic rhinitis
out of season: starting 24 hours after the final dose, daily allergen challenges were given for seven days
(NCT00770003). Safety, tolerability, pharmacokinetics, and biomarkers were monitored. During the allergen
challenge series, nasal symptoms and lavage fluid levels of tryptase and α2-macroglobulin, reflecting mast cell
activity and plasma exudation, were monitored.
Results: AZD8848 produced reversible blood lymphocyte reductions and dose-dependent flu-like symptoms: 30–
100 μg produced consistent yet tolerable effects. Plasma interleukin-1 receptor antagonist was elevated after
administration of AZD8848, reflecting interferon production secondary to TLR7 stimulation. At repeat challenge/
treatment, AZD8848 reduced nasal symptoms recorded ten minutes after allergen challenge up to eight days after
the final dose. Tryptase and α2-macroglobulin were also reduced by AZD8848.
Conclusions: Repeated intranasal stimulation of Toll-like receptor 7 by AZD8848 was safe and produced a
sustained reduction in the responsiveness to allergen in allergic rhinitis.
Trial registration: NCT00688779 and NCT00770003 as indicated above.
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As suggested by the hygiene hypothesis, infections are of
importance to the maturation of the immune system [1].
Th1-mediated immunity may be defective in a modern
clean environment resulting in facilitation of Th2
responses associated with allergic disorders [2,3]. Con-
versely, up-regulated Th1 responses, e.g. as a consequence
of infections, can be associated with reduced Th2 activity
and reduced responsiveness to allergen [4]. Controlled* Correspondence: lennart.greiff@live.se
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reproduction in any medium, provided the orinfection-like stimulation of the immune system may in
this context be beneficial, and may be achieved by the use
of Toll-like receptor (TLR) agonists.
TLRs are receptors of the innate immune system that
recognise conserved microbial components known as
pathogen-associated molecular patterns (PAMPs) [5].
PAMPs include the bacterial product LPS, viral single-
stranded RNA, and bacterial/viral CpG DNA, acting as
TLR4, TLR7, and TLR9 ligands, respectively [6]. Activa-
tion of TLRs stimulates the innate immune system, poten-
tially leading to down regulation of Th2 adaptive
responses to allergen [6]. The possibility of skewing the
immune system away from a Th2 response, as has beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for the development of TLR agonists as treatments for al-
lergic rhinitis and asthma.
In a murine model of allergic asthma, a TLR7 ligand
(S28463) administered systemically exerted anti-allergic
effects resulting in attenuated airway eosinophilia, nor-
malized airway responsiveness, and prevention of airway
remodelling [11,12]. In a similar model, Sel et al. [13]
demonstrated that systemic intervention with poly(I:C)
and R-848, viral ligands recognized by TLR3 and TLR7
respectively, prevented production of allergen specific
IgE and IgG1 during sensitisation and subsequently alle-
viated experimental asthma. Moreover, administration of
poly(I:C) and R-848 in established allergy markedly
reduced the responsiveness to allergen [13]. Similarly,
the TLR9 ligand 1018 ISS was shown to inhibit Th2-
mediated airway inflammation and hyperresponsiveness
in animals [14-18].
AZD8848 is a selective TLR7 agonist optimised for
topical airway treatment through rapid metabolism by
plasma esterases, thereby reducing systemic exposure
[19]. Observations involving peripheral blood mono-
nuclear cells (PBMCs) and ovalbumin-sensitized spleno-
cytes indicate that stimulation of TLR7 by AZD8848
inhibits Th2-adaptive responses to allergen via an im-
mune response involving the induction of mediators in-
cluding interferon alpha (IFN-α) [19-22]. Furthermore,
Ikeda et al. [23] reported that AZD8848 was effective
against allergen-induced airway obstruction and inflam-
mation in guinea-pig models of rhinitis and asthma with
weekly as well as acute dosing.
Here, we report the results of two studies. In the first
study, increasing single doses of AZD8848 were admi-
nistered intranasally to healthy subjects and patients
with allergic rhinitis. Indices of efficacy and tolerance
were monitored. In the second study, AZD8848 was
administered intranasally once weekly for five weeks to
patients with allergic rhinitis: these individuals were then
subjected to repeat allergen exposure and disease activity
was monitored focusing on symptoms to establish proof
of principle.Methods
Study description
This report comprises two studies evaluating safety and ef-
ficacy of single and repeated doses of AZD8848 adminis-
tered to the nasal airway, both approved by the Regional
Ethics Committee and the Swedish Medical Product
Agency. They were conducted according to the Declar-
ation of Helsinki and in compliance with Good Clinical
Practice, and informed consent was obtained. The studies
were of randomized, placebo-controlled, double-blinded,
and parallel group designs. Reprotoxicology data waslacking for AZD8848 at the time of these studies and men
only were recruited.
Single ascending dose study (NCT 00688779)
Subjects
Eight single ascending intranasal doses of AZD8848 (0.3-
600 μg) were given to healthy subjects (n = 48, mean age
26, range 19–44), in groups each involving four indivi-
duals receiving AZD8848 and two receiving placebo.
Once a maximum tolerated dose was determined,
patients with allergic rhinitis (n = 12, mean age 25, range
22–28) received single doses of AZD8848 (30 and
100 μg) and placebo.
Exclusion criteria for healthy individuals were: any
relevant disease including seasonal and perennial allergic
rhinitis, asthma, clinically relevant structural nasal ab-
normalities, and upper respiratory tract infection within
two weeks prior to the start of the study.
Inclusion criteria for patients were: men with seasonal
allergic rhinitis for at least two years, positive skin prick
test to birch or grass pollen allergen, asymptomatic con-
dition outside the pollen season, and need for treatment
at seasonal allergen exposure.
Exclusion criteria for patients were: any relevant dis-
ease including perennial allergic rhinitis, asthma, clinic-
ally relevant structural nasal abnormalities, upper
respiratory tract infection within two weeks prior to the
start of the study, use of topical corticosteroids within
four weeks prior to the study and use of antihistamines
within one week, and immunotherapy.
Study drug
The study product was a solution of AZD8848 (60 mg/g),
diluted with sterile buffered saline to concentrations
required for each dose level. It was administered using
a nasal spray device delivering 50 μL per actuation.
The placebo product was isotonic saline. The study
product was provided in 10 mL amber glass vials fitted
with pump spray devices. In order to assure compli-
ance, study personnel administered the doses. To pre-
vent bronchial airway deposition of the drug, the
patients were instructed to exhale against a resistance
(30 cm H20), to functionally close the connection be-
tween the nasal and bronchial airways, while the study
drug was administered.
Measurements
Pharmacokinetic parameters were monitored. Further-
more, plasma interleukin-1 receptor antagonist (IL-1Ra)
was measured, reflecting type-1 IFN generation down-
stream from TLR7, and blood lymphocyte counts were
carried out. An extensive safety investigation was per-
formed with laboratory measurements (haematology,
clinical chemistry, and urine analysis), inspection of the
Greiff et al. Respiratory Research 2012, 13:53 Page 3 of 10
http://respiratory-research.com/content/13/1/53nose (before and 24 hours after dose), vital signs (blood
pressure, pulse, and body temperature), and continuous
ECG. Finally, AEs were monitored and recorded with in-
formation about seriousness, causality, intensity, action
taken, recovery, and outcome.
Repeat challenge/treatment study (NCT 00770003)
Subjects
AZD8848 was given once per week for five weeks. In a
first part (Part A), 18 patients were assessed at two dose
levels (30 and 60 μg) (mean age 24 years, range 19–39)
(Table 1). These individuals were resident at the clinic
until 24 hours after each dose and subjected to intense
safety monitoring. Of these subjects six received 30 μg
AZD8848, six 60 μg AZD8848, and six placebo. In a sec-
ond part (Part B), 56 patients were examined in an out-
patient setting: 28 received 60 μg AZD8848 and 28
received placebo (Table 1). In both groups (Part A as
well as B), starting 24 hours after the final dose, daily al-
lergen challenges were performed for seven days. Data
from Part B were analyzed together with the twelve sub-
jects from Part A who either received 60 μg AZD8848
or placebo: progress through the Repeat challenge/
treatment study is described in Figure 1. The mean age of
these 68 patients was 27 years (range 18–46). Inclusion
and exclusion criteria for the patients were the same as
described in the dose finding study above for patients with
allergic rhinitis.
Study drug
The study product was AZD8848 (0.3 and 0.6 mg/mL)
in buffered saline. It was administered using a nasal
spray device delivering 50 μL per actuation. The placebo
product had the same composition except for AZD8848.
In Part A, 30 or 60 μg AZD8848 was administered once
per week for five weeks (i.e. 15 or 30 μg per nasal cavity).
In Part B, 60 μg AZD8848 was given once per week for
five weeks (i.e. 30 μg per nasal cavity). In order to assure
compliance, study personnel administered all doses. To
prevent bronchial airway deposition of the drug, theTable 1 Design of the repeat challenge/treatment study (Part
Study week 1 2 3
1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3
Treatment X X X
Allergen
Symptoms
Plasma X X X X
Nasal lavage X
Nasal symptoms were scored ten minutes after each allergen challenge as well as e
Note that post challenge and evening symptoms were recorded from day 2 of Stud
from day 3 of Study week 5 to day 2 of Study week 6. On the first days of Study we
drug. The plasma samples were used to monitor safety parameters, pharmacokinetpatients were instructed to exhale against a resistance
(30 cm H20), to functionally close the connection be-
tween the nasal and bronchial airways, while the study
drug was administered.
Measurements 1
Pharmacokinetic characteristics were explored only in
Part A (n = 18). AZD8848 was not expected to be detect-
able in plasma due to rapid and complete metabolism.
Therefore, exposure was monitored through analysis of
its acid metabolite. Blood samples were obtained before
and 15 minutes and 0.5, 1.0, 1.5, 2.0, and 4.0 hours after
the first and fifth study drug administration in Part A.
Analysis of AZD8848 and its acid metabolite was per-
formed using ethanol extraction followed by liquid chro-
matography and tandem mass spectrometry.
Plasma samples for analysis of IL-1Ra were obtained
during the Part A study period prior to and 24 hours fol-
lowing the first, third, and fifth administration of the
study drug. In Part A (n = 18), the same safety variables
were monitored as in the single ascending dose study. In
Part B, safety monitoring was reduced to vital signs, clin-
ical chemistry, and ECG at pre-dose, prior to the third
dose, 24 hours after the fifth dose, and at follow-up. In
addition, a flow-cytometric analysis of lymphocyte sub-
sets was performed. AEs were recorded continuously in
both groups as described for the single ascending dose
study above.
Allergen challenge model
In order to establish individually tolerable, repeatable, yet
symptom-producing allergen challenge-doses, a nasal ti-
tration procedure was performed [24]. In the allergen ti-
tration scheme, increasing doses of birch or grass pollen
allergen were administrated at ten-minute intervals using
a spray-device delivering 100 μL per actuation (Aquagen,
ALK-Abelló, Hørsholm, Denmark). One puff was adminis-
tered into each nostril resulting in effective doses of 100,
300, 1.000, and 3.000 SQ units per nasal cavity. This
scheme was followed until the subject responded with atA and B)
4 5 6
4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2
X X
X X X X X X X
X X X X X X X X
X X
X X
very morning and evening during the seven days’ allergen challenge series.
y week 5 to day 1 of Study week 6, while morning symptoms were recorded








AZD8848 30 µg (n=6) AZD8848 60 µg (n=34) Placebo (n=34)










Figure 1 Patient flow through the repeat challenge/treatment study (participants in Part A as well as Part B). The progress was
characterized by very few dropouts (2.7%).
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on a scale from 0 to 3 for either nasal secretion or nasal
blockage. The dose that produced the desired effect was
chosen for the allergen challenge series and was given in
the morning once daily for seven days, starting 24 hours
after the final dose of the study drug.
Measurements 2
During the allergen challenge series, the patients scored
nasal symptoms every morning and evening. The scores
were entered into diary cards and each registration
reflected the preceding twelve hours. Nasal secretion
and blockage as well as the most severe of sneezing and
itching were scored separately on a four-grade scale:
0 = no, 1 =mild, 2 =moderate, and 3 = severe symptoms.
The scores were added to a daily total nasal symptom
score (TNSS), with separate morning and evening
scores. Nasal symptoms were also scored ten minutes
post allergen challenge: secretion and blockage were
scored as described above, whereas the number of
sneezes were counted and transformed into a sneezing
score by the investigators: 0 sneezes = 0, 1–4 sneezes = 1,
5–9 sneezes = 2, and 10 or more sneezes = 3. The scores
were added to a daily post challenge TNSS.
Nasal saline lavages were obtained at three occasions,
i.e. prior to administration of the study drug (baseline
observation), 24 hours after the final dose, and 24 hours
after the final allergen challenge. Nasal lavages were car-
ried out using a pool-device containing 15 mL fluid and
the right nasal cavity was used at all occasions [25]. Each
lavage had a five-minute duration. The recovered lavage
fluids were centrifuged and the supernatants werehomogenized, prepared in aliquots, and frozen (−30°C).
The samples were subjected to analysis of α2-macroglo-
bulin and tryptase, reflecting plasma exudation and mast
cell activity, respectively.
α2-Macroglobulin in nasal lavage fluids was measured
using a radioimmunoassay sensitive to 7.8 ng/mL. Tryp-
tase was measured using a radioimmunoassay with de-
tection limit of 0.5 ng/mL (Pharmacia-Diagnostics,
Uppsala, Sweden). While α2-macroglobulin was analysed
in the lavage fluids as they were, samples were concen-
trated ten times before the analysis of tryptase. In
plasma, IL-1Ra was measured using a commercial ELISA
(Invitrogen, Carlsbad, CA).Statistics
In the single ascending dose study, only descriptive statis-
tics were used. Similarly, descriptive statistics only were
employed for pharmacokinetic observations and safety
variables. In the repeat challenge/treatment study, an
ANOVA model was used for comparison between treat-
ments (AZD8848 60 μg vs. placebo): TNSS recorded post
challenge and at morning and evening observations were
analyzed separately. P-values refer to one-sided hypothesis
testing: values <0.05 were considered statistically signifi-
cant. A multiplicative model was used for biomarkers by
log transformation of the response variable and the covari-
ate (i.e. a baseline value). If there was a value below limit
of quantification (LOQ) in this analysis, it was estimated to
LOQ/2. Treatment differences were estimated from re-
spective model and confidence intervals, and p-values were
calculated. In the repeat challenge/treatment study, the six
Table 2 Side effects of different doses of AZD8848 in
healthy subjects (the single ascending dose study): each
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included in the comparative analysis as they were so few.group comprised four individuals and the figures
indicate the number of subjects reporting a particular
experience (by preferred term)
Dose (μg)
0.3 1 3 10 30 100 300 600
Headache 1 0 0 1 0 3 3 4
Epistaxis 1 0 0 0 1 1 1 4
Pharyngeal pain 0 0 0 0 1 0 0 3
Pyrexia 0 0 0 0 0 2 1 3
Rhinorrhea 0 0 0 0 0 2 1 2
Nasal blockage 0 0 0 0 2 1 0 0
Nasal ulcer 0 0 0 0 0 0 2 1
Nasopharyngitis 1 0 0 0 0 0 1 0
Malaise 0 0 0 0 0 0 0 1Results
Single ascending dose study
AZD8848 was not measurable in plasma, whereas its
acid metabolite was readily detected. For the 30 and
100 μg doses, respectively, mean maximum plasma con-
centration (Cmax) was 0.27 and 0.65 nmol/L, time to
Cmax (tmax) was 15.0 and 22.5 min, and half-life (t1/2)
was 18.4 and 27.6 min in healthy volunteers. Mean Cmax
increased with increasing dose levels to a maximum of
1.55 nmol/L with the 600 μg dose. Area under the curve
(AUC) increased roughly linearly with ascending dose.
The first dose that consistently produced systemic
effects in terms of lymphocyte reductions (Figure 2A)
and elevations of plasma IL-1Ra (data not shown) wasFigure 2 Mean blood lymphocyte counts in the dose finding
study (A) and the repeat challenge/treatment study (B).
AZD8848 produced dose-dependent and repeatable lymphocyte
reductions. The reductions were reversible and global, involving CD3+,
CD4+, CD8+, and CD20+ cells (data not shown).
Myalgia 0 0 0 0 0 1 1 2
The most common event was flu-like symptoms occurring within 24 hours and
disappearing within 48 hours. The second most common event was epistaxis,
i.e. blood-admixed nasal secretions. The side effects were dose-dependent and
considered causally related to the treatment.30 μg. No other specific changes were revealed by the la-
boratory blood/plasma analysis.
AZD8848 produced dose-dependent influenza-like
symptoms starting consistently at 100 μg and leading to
termination of dose escalations above 600 μg (Table 2).
The second most common effect was mild epistaxis, i.e.
blood-admixed nasal secretions.
Following the experiments involving healthy indivi-
duals, patients with allergic rhinitis (examined out of
season) were subjected to administration of AZD8848
(30 and 100 μg). No differences were observed in theFigure 3 Mean plasma levels of AZD8848’s acid metabolite
from the first group of the repeat challenge/treatment study
after administration of 60 μg of the study drug. The metabolite
increased rapidly and returned to baseline levels after four hours.
Figure 4 IL-1Ra in plasma obtained at Study weeks 1, 3, and 5 from the repeat challenge/treatment study (symbols indicate individual
values: n = 6). IL-1Ra increased 24 hours after nasal administration of AZD8848 and the effect was consistent and repeatable (p< 0.001).
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the healthy individuals.Figure 5 Mean total nasal symptoms recorded ten minutes
after each daily allergen challenge during the seven days’
challenge series. AZD8848 (60 μg) reduced symptoms recorded
ten minutes after challenges from challenge day four and onwards
(p< 0.05). Vertical bars indicate SEM.Repeat challenge/treatment study
AZD8848’s acid metabolite was detected at doses of
30 μg (data not shown) as well as 60 μg (Figure 3) For
the 60 μg dose, as monitored on Study week 1 and 5, re-
spectively, Cmax was 0.58 and 0.57 nmol/L, tmax was 17.2
and 20.2 min, and t1/2 was 0.83 and 1.26 hours.
Plasma levels of IL-1Ra, reflecting TLR7-induced type-1
IFN production, were consistently increased 24 hours after
nasal administration of AZD8848 (Figure 4). For 60 μg,
these changes reached statistical significance (p< 0.001).
(For 30 μg, comparative statistics was not carried out.)
In agreement with the single dose study, blood lympho-
cyte counts were consistently reduced after administration
of AZD8848 in the repeat challenge/treatment study
(Figure 2B). Further analysis indicated that this reflected
uniform reductions across different lymphocyte subsets:
CD3+, CD4+, CD8+, and CD20+ cells (data not shown).
The safety profile in the repeat dose/treatment study
was similar to what is described for the single dose study
above, with 35 and 24% reporting flu-like symptoms and
blood-admixed nasal secretions, respectively, at treat-
ment with 60 μg AZD8848 (c.f. 6 and 6% for placebo).
The symptoms subsided within 24 hours, and did not
lead to any individual discontinuations. Two individuals
did drop out of the study and both received 60 μg
AZD8848: one and two doses, respectively. One case
was an AE (anorectal irritation, considered not asso-
ciated with the treatment) and the other was an individ-
ual found to be wrongfully included.In patients receiving placebo, in agreement with previ-
ous observations in this model [24], increases were
observed for nasal symptoms, i.e. TNSS: total nasal
symptom score, ten minutes after each allergen chal-
lenge. Morning and evening total nasal symptoms were
also increased and consistent changes were observed
from the third study day of the allergen challenge series.
AZD8848 (60 μg) reduced nasal symptoms recorded ten
minutes after allergen challenge from the fourth through
the seventh day of the challenge series (i.e. five to eight
days after the last dose of AZD8848) with an estimated ef-
fect size of 0.74 score units (p< 0.05) (Figure 5). For indi-
vidual symptoms, reductions were observed for itching
Table 3 Mean ratios (between AZD8848 and placebo) for
levels of α2-macroglobulin and tryptase, respectively, in
nasal lavages obtained 24 hours after the last allergen
challenge in the repeat challenge/treatment study
Variable Mean ratio 95% CI P-value
α2-Macroglobulin 0.50 0.25-0.97 0.020
Tryptase 0.62 0.35-1.10 0.049
α2-Macroglobulin was reduced in patients who had received AZD8848
(p< 0.05, c.f. placebo). Similarly, lower levels of tryptase were observed in this
group (p< 0.05, c.f. placebo).
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< 0.05), but not for runny nose (data not shown).
Morning and evening symptoms were numerically
reduced on challenge days two through five in patients
receiving AZD8848 (60 μg), but these effects failed to
reach statistical significance (Figure 6): p> 0.05 for
morning as well as evening symptoms.
On the day after the last allergen challenge, levels of
α2-macroglobulin in nasal lavage fluids, reflecting plasma
exudation, were lower in patients who had received
60 μg AZD8848 and this was statistically significant
compared to placebo (p< 0.05) (Table 3). Significantly
lower levels of mast cell tryptase were also seen in these
patients (c.f. placebo) (p< 0.05) (Table 3).Figure 6 Mean total nasal morning (upper panel) and evening
(lower panel) symptoms, each reflecting the preceding twelve
hours, during the allergen challenge series. Symptoms were
reduced on challenge days two through five in patients receiving
AZD8848 (60 μg) compared with placebo, but these changes failed
to reach statistical significance. Vertical bars indicate SEM.Discussion
In these studies we demonstrate that repeated intranasal
TLR7 stimulation is associated with reduced responsive-
ness to allergen in patients with allergic rhinitis. It is the
first observation in man where TLR7 has been success-
fully evaluated as a therapeutic target for allergic airway
inflammation.
The TLR7 agonist AZD8848 undergoes very rapid en-
zymatic degradation by butyrylcholinesterase: t1/2 in
human plasma is estimated to be 20 seconds [19]. In this
study, this was reflected by undetectable plasma levels of
the substance following nasal administration of doses up
to 600 μg, while its acid metabolite, which is 1500 times
less potent at the receptor [19], was detectable at doses
of 30 μg and above. Nevertheless, flu-like symptoms
were reported, which were probably secondary to local
TLR7 activation and a subsequent systemic increase in
type-1 IFN. This possibility was indicated by the five-
fold increase in plasma IL-1Ra following administration
of AZD8848, known to reflect type-1 IFN production
down-stream to TLR7 (i.e. proof of mechanism) [21,26].
In the context of the hygiene hypothesis, repeated ad-
ministration of the TLR7 agonist AZD8848 may mimic
repeated virus-like stimulation of the immune system.
In the repeat challenge/treatment study, acute symp-
toms in response to allergen were consistently reduced
from the third day of the allergen challenge series in
patients receiving the TLR7 agonist when compared to
placebo, indicating a sustained effect of at least one week
after the final dose of AZD8848. The same pattern was
observed for the low-grade morning and evening symp-
toms, but these changes failed to reach statistical signifi-
cance. In agreement with a symptom reducing effect,
lavage fluid levels of tryptase and α2-macroglobulin,
reflecting mast cell activity and inflammatory plasma ex-
udation [27,28], were also reduced. Our observations ex-
tend recent in vitro and animal reports on anti-allergic
effects of AZD8848, indicating that repeated TLR7 stimu-
lation reduces the responsiveness to allergen [19-23], and
suggest that AZD8848 may be clinically effective in aller-
gic rhinitis.
The observed reduction in responsiveness to allergen
might reflect that the immune system was functionally
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not represent repolarisation of T-lymphocytes (i.e. a
change from Th2 to Th1 phenotype), as this study
involved atopic individuals with established populations
of memory T-cells with a life span of at least two to
three years [29]. Arguably, the outcome was more likely
a consequence of a functionally reduced responsiveness
of memory Th2 lymphocytes. In this context, for future
studies, it would be of interest to examine if prolonged
treatment, i.e. a time period sufficient to induce true
repolarisation of T-lymphocytes, could produce a more
marked anti-allergic effect.
While the repeat challenge/treatment study demon-
strated that 60 μg of AZD8848 administered intranasally
once weekly for five weeks induced a desired hypore-
sponsiveness to allergen, likely through activation of
TLR7, further studies are warranted to optimize the ef-
fect. Preclinical data have indicated that more frequent
administration of AZD8848 can produce more marked
anti allergic effects (AstraZeneca: data on file). Further-
more, as demonstrated in a Brown Norway rat model of
allergic rhinitis/asthma, both nasal and bronchial admin-
istration of AZD8848 can reduce the ability of a bron-
chial allergen challenge to produce bronchial airway
eosinophilia and generate IL-13 [19], suggesting the pos-
sibility that nasal administration of AZD8848 may be ef-
fective in the treatment of asthma.
In this study, safety and tolerability of intranasal
AZD8848 was evaluated parallel to the exploration of its
anti-allergic effects. None of the patients treated with
AZD8848 discontinued the study prematurely due to
drug-related AE. Furthermore, standard laboratory indices
(haematology, clinical chemistry, and urine analysis) were
unaffected by the treatment, except for the anticipated
transient reductions in blood lymphocyte counts. Moreover,
vital signs (blood pressure, pulse, and body temperature)
and continuous ECG were unaffected. However, dose-
dependent local side effects were common, albeit of mild
intensity. These were dominated by blood-admixed nasal
secretions and in these cases nasal inspection revealed
superficial mucosal irritations/ulcerations. This effect, and
the temporary flu-like symptoms that were experienced by
a third of the patients, needs to be further evaluated in
order to assess overall tolerability of intranasal AZD8848
as a potential treatment.
The body of knowledge on TLRs is increasing as their
distribution and functions are outlined, along with po-
tential associations with specific allergic and airway con-
ditions [30,31] and their treatment, notably specific
immunotherapy [32,33]. In the context of established al-
lergic airway conditions, animal observations suggest
that stimulation of TLRs (i.e. TLR3, TLR4, TLR7, TLR8,
and TLR9) has a general potential to reduce allergen re-
sponsiveness. However, focusing on human conditionsavailable observations are scarce. In patients with allergic
asthma, a synthetic oligonucleotide containing immunos-
timulatory CpG motifs (acting on TLR9) was reported to
increase the expression of IFN-γ and IFN inducible genes
without affecting allergen challenge induced changes [34],
possibly reflecting that the dose employed was too low to
produce an anti-allergic effect. In a report by Casale et al.
[35], which focused on tolerability to topical CRX-675
(acting on TLR4), data on efficacy was not given in detail,
but a decrease in allergen-induced nasal symptoms was
reported in one of four treatment groups compared with
placebo. Moreover, it was recently reported that nasal ad-
ministration of a TLR8 agonist (i.e. VTZ-1463) improved
symptoms of allergic rhinitis [36]. Taken together, avail-
able information suggests that TLR agonists are valid
treatment targets for allergic airway disease.
The natural ligand for TLR7 is single stranded RNA.
Accordingly, various respiratory viruses, e.g. influenza,
corona, and potentially rhinovirus [37], may activate the
receptor. In this context, it is of interest to consider the
evidence indicating that respiratory viral infections
often heighten the responsiveness to allergen and pro-
duce asthma exacerbations [38,39]. The possibility that
acute pro-inflammatory effects of TLR7 stimulation
may heighten the responsiveness to allergen while later
effects may reduce allergen responsiveness suggests that
the timing of interventions with TLR7 agonists in rela-
tion to allergen exposure is important. Further studies
are warranted to explore this and to outline the benefits
and risks of treatment with TLR7 agonists in allergic air-
way disease.Conclusion
We conclude that repeated intranasal stimulation of
TLR7 by AZD8848 has a potential to affect the immune
system in a way that may result in a sustained reduction
in the responsiveness to allergen in allergic rhinitis.Competing interests
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